Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

ConclusionAs an adjuvant treatment of stage IIB or IIC melanoma, pembrolizumab was estimated to reduce recurrence, extend patients ’ life and QALYs, and be cost-effective versus observation at a US willingness-to-pay threshold.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research